News and Announcements
Actinogen Expected to Treat First Patient Within Weeks
- Published April 26, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Actinogen Medical (ASX: ACW) is pleased to provide a summary of its progress over the quarter ended 31 March 2017.
KEY TAKEAWAYS:
- Significant progress achieved with XanADu, Actinogen Medical’s Phase II clinical trial of Xanamem™ in Alzheimer’s disease.
- 17 of a total planned 20 trial sites globally have been selected, with four of these actively recruiting patients.
- Treatment of first patient expected to start within weeks.
- XanADu represents a landmark in the global search for an effective treatment for Alzheimer’s disease and reinforces Australia’s role at the forefront of Alzheimer’s disease research.
- Recruitment follows regulatory approval received for XanADu in the US, the UK and Australia during the quarter.
- Healthcare industry and venture capital veteran, Dr Geoff Brooke, appointed as Chairman.
- Cash at 31st March 2017 of $5.2 million.
Actinogen Medical has made significant progress during the quarter with XanADu and expects to recruit the first patients for this landmark trial within weeks.
The Company remains focused on ensuring the trial progresses as expected and looks forward to updating the market on its progress over the near to medium term. Topline trial results are expected in early 2019.
“We have made excellent progress over the past few months with XanADu and expect to announce the successful recruitment of the first patient imminently. This ground breaking trial shows that Australia is leading the way in developing this promising new treatment for Alzheimer’s disease,” said Dr Bill Ketelbey, CEO of Actinogen Medical.
“The development of Xanamem could potentially be one of the most significant contributions Australian clinical development will make to the management of Alzheimer’s disease- a disease presenting as the next major global health challenge for which new treatments are desperately needed.”
Actinogen Medical (ASX:ACW) is an ASX-listed biotech company focused on innovative approaches to treating cognitive decline that occurs in chronic neurodegenerative and metabolic disease. Actinogen medical is developing Xanamem™ a promising new therapy for Alzheimer’s disease, a condition with a multibillion dollar market potential.
Company Updates
Forget Startups: Why Magnetic Alliance is Betting on “Boring” Mid-Market Turnarounds
While Australia’s venture capital scene spent years chasing unprofitable tech startups and speculative high-growth plays, Mark Lim was quietly taking a radically different path. The Managing Partner of Magnetic Alliance Capital sees the nation’s richest investment opportunities hiding in plain sight: inside thousands of unglamorous, profitable, but operationally sluggish mid-market businesses. Speaking on Wholesale Investor’s […]
The asset class where the market has no vote
Litigation funding returns are decided in a courtroom, not a cycle. Knightsbridge’s Head of Capital is careful to call that a different risk rather than a lower one, and his answer to it is spread, not concentration. Most alternative assets still answer to something. Property answers to rates. Private credit answers to defaults. Even the […]
The listing fee vendors pay whether the house sells or not
Australia’s property portals collect more than $2 billion a year while national listings sit flat. An Australian-built AI platform is targeting the economics, not just the interface. An Australian vendor listing a home pays a vendor-paid advertising fee on top of agency commission. Rama Dwarapudi, Founder and Chief Executive Officer of RealSearch, puts a typical […]
Backed By Leading Investment Groups and Family Offices
